PAQ Therapeutics Closes $30 Million Round for Autophagy-Caused Degredation
July 15, 2021 at 05:49 AM EDT
PAQ Therapeutics, a Cambridge , Mass. autophagy company, closed a $30 million Series A round from China investors. The company develops novel small molecule autophagosome-tethering compounds (ATTECs) designed to catalyze autophagy-dependent degradation of disease-causing substrates. PAQ's initial target is Huntington's Disease. The A round was led by Sherpa Healthcare Partners with Huagai Capital, MSA Capital, and MRL Ventures Fund participating, joined by seed investors, Nest.Bio Ventures and Matrix Partners China. More details.... Share this with colleagues: // //
